Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

rding the company's future plans, objectives, performance, growth or the company's underlying assumptions. The words "may", "would", "will", "expect," "intend", "plan", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: that HspE7 is more active with an elevated does of adjuvant; that administration of HspE7 induces T-cell responses that are therapeutic; that administration of HspE7 results in an E7-specific T-cell immune response; that such an immune response may be associated with objective clinical responses in patients with CIN; that HspE7 may successfully induce a targeted immune response to effectively treat CIN; the potential of HspE7 to treat HPV-16 induced CIN; and initiation of our Phase 2 clinical study in patients with CIN 2/3 in mid-2008.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunology responses may not be a predictor of clinical benefit; that immunological findings in our first three cohorts may not be consistent with findings from our fourth cohort and future clinical studies; that safety and tolerability findings in all four cohorts may not be consistent with findings from future clinical studies; that results from future clinical trials will not be consistent with our expectations; that we will not be able to recruit patients
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Levosimendan - ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary risk ... information. Pipeline Developer is a ...
... Aug. 16, 2011 Medicare Part D beneficiaries who ... 100 percent of previously subsidized prescription costs, are twice ... to switch to more affordable or generic medications, a ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The study ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 This is ... of the global Sterilizers industry with a focus on ... the market status of the Sterilizers manufacturers and is ... and individuals interested in the industry. This report provides ... applications and manufacturing technology. In this part, the report ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the ... the company announces big discounts on its bamboo ... , BambooFlooringChina.com is the world’s leader in bamboo flooring. ... until Jan. 20, 2015. , The bamboo mats are ... natural thread. All the bamboo strips for the mats ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... In the 1960s, surgeons experimented by transplanting chimpanzee organs into ... Fae received a baboon heart and survived 20 days. Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... treatment option for HIV patients is associated with an ... new study. However, researchers say the benefit of the ... most patients. ,Combination antiretroviral therapy substantially improves ... Before this therapy was available, the annual mortality rate ...
... condition that has existed for centuries, doctors say. But only ... or CDH, defined as migraines or neck- and head-squeezing tension ... ,Some might think it sounds like just another ... Gohmann, an 18-year-old college freshman from St. Cloud, Minnesota, know ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... authorities have determined that green onions likely caused a ... more than 500 people and killed three.//, ,Bill ... that health officials confirmed that Chi-Chi's employees were not ... they could have done to prevent the outbreak and ...
... a new drug alternative to warfarin in reducing stroke among ... the drug ximelagatran appears to be as effective as warfarin.// ... high risk of stroke because of its blood thinning capability. ... risk of bleeding and a possible interaction with food and ...
Cached Medicine News:Health News:Animals can give us a second chance at life 2Health News:HIV Treatment Said to Increase Heart Attack Risk 2Health News:Finding relief from Excruciating Headaches a challenge 2Health News:Finding relief from Excruciating Headaches a challenge 3
Peapod Rongeur, 5.5 length 140 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
... first skull pin to utilize cutting edges instead of ... way into bone the Hifix pin drills a neat ... initial fixation over standard skull pins. The Hifix pin ... pins and in the bremer 3D halo crown. Hifix ...
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: